Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06529302 · ClinicalTrials.gov registry record

The OPBC-07/microNAC Study

A clinical trial of Breast Cancer, sponsored by University Hospital, Basel, Switzerland.

Active
Registry status
2,000
Enrollment target
20
Study locations

NCT06529302 is a study of Breast Cancer that is active but no longer recruiting, run by University Hospital, Basel, Switzerland. The registered enrollment target is 2,000 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06529302, a study of Breast Cancer, is active but no longer recruiting, sponsored by University Hospital, Basel, Switzerland.

ACTIVE NOT RECRUITING
Registry status
2,000 participants
Enrollment target
20
Study locations

Study Summary

The aim of this multicenter retrospective cohort study is to determine the safety of omission of axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy.

Conditions Studied

Study Locations (20)

New York

  • NYU Langone Health - New York
  • Memorial Sloan Kettering Cancer Center - New York
  • Montefiore Medical Center - New York
  • University of Rochester - Rochester

California

  • Cedars-Sinai Medical Center - Los Angeles
  • University of California - San Francisco
  • Providence Saint John's Cancer Institute - Santa Monica

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • Fox Chase Cancer Center - Philadelphia
  • University of Pittsburgh Medical Center - Pittsburgh

Washington

  • Swedish Cancer Institute - Seattle
  • University of Washington - Seattle

Arizona

  • Valleywise Health Medical Center - Phoenix

Florida

  • University of Miami - Coral Gables

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2024-05-15
Est. Completion 2025-06

What the Registry Record Tells You About NCT06529302

The ClinicalTrials.gov registry entry for NCT06529302 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (29% lower). The listed sponsor is University Hospital, Basel, Switzerland, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT06529302 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, California, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06529302 about?

NCT06529302 is a clinical study titled "The OPBC-07/microNAC Study". The aim of this multicenter retrospective cohort study is to determine the safety of omission of axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy.

What is the current status of trial NCT06529302?

This trial is currently active not recruiting. The enrollment target is 2,000 participants. The study started on 2024-05-15. Estimated completion is 2025-06.

What conditions does trial NCT06529302 study?

This clinical trial studies the following conditions: Breast Cancer.

Who is sponsoring clinical trial NCT06529302?

This trial is sponsored by University Hospital, Basel, Switzerland, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06529302 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.